EUROPE IMMUNOGLOBULIN MARKET 2022-2028

Lifesciences | Diagnostic & Biotechnology

EUROPE IMMUNOGLOBULIN MARKET 2022-2028

Market by Type, Delivery Mode, Application, End-user, Sales Channel, and Country Outlook | Forecast 2022-2028

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

A study by Triton Market Research on the European immunoglobulin market shows that it will progress with a CAGR of 6.81% during the forecasted period of 2022-2028


Report scope can be customized per your requirements. Request For Customization

The countries studied in this market include:

•         The United Kingdom

•         Italy

•         Spain

•         France

•         Germany

•         Rest of Europe

The immunoglobulin market in the region is primarily driven by the prevalence of various immunodeficiency diseases found in the population. Alongside the government initiatives regarding immunoglobulin and plasma donation and the biotechnology sector’s development, the research and development of various vaccines are also expected to drive market growth. Furthermore, this is expected to increase the demand for technological advancement and innovative immunoglobulin systems. 

In Germany, the research and development activities relating to antibody development alongside the policies and programs supported by the government are the growth promoters of the market. For example, in 2020, to understand the prevalence of the coronavirus, German scientists started a nationwide study for testing the measures to prevent the spread of the virus. Furthermore, in the same year, the country planned on launching its first antibody testing program, conducting a series of blood tests to determine the number of people immune to infections and the ones who were infected without knowledge. Thus, such factors are expected to increase the market growth in Germany during the forecasted period. 

Italy has also seen a rise in the demand for immunoglobulin in recent years. The increase in the prevalence of neurological diseases such as dementia, Alzheimer’s, and others drives the demand for immunoglobulin. These diseases have been marked as the latest postulated indications for the clinical use of immunoglobulin. Hence, the increase in the prevalence of such a disease is expected to foster the immunoglobulin market’s growth across the country in the forecast period. 

Primary immunodeficiency diseases are rare genetic disorders that weaken the immune system. Some of these primary immunological deficiencies can lead to death. Depending on the disease’s severity, primary immunodeficiency illnesses may be detected during childhood, adolescence, or adulthood. The increasing prevalence and incidence rates of autoimmune illnesses and immunodeficiency diseases are anticipated to boost the demand for and acceptance of immunoglobulin products, which is predicted to support market expansion throughout the forecast period.

The studied report assesses the market’s growth based on type, delivery mode, application, end-user and sales channel. Here, the application segment comprises hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Guillain-Barre syndrome, inflammatory myopathies, specific antibody deficiency, and other applications.

The dominant players in the immunoglobulin market include Sichuan Yuanda Shuyang Pharmaceutical Co Ltd, Biotest AG, ADMA Biologics, Shanghai RAAS Blood Products Co Ltd, Pfizer Inc, Sanquin Plasma Products BV, Takeda Pharmaceutical Company Limited, and CSL Behring. 

Founded in 1983, Octapharma AG is the largest independent, privately-held plasma fractionator in the world. Headquartered in Switzerland, Octapharma AG is one of the leading human protein product manufacturers. High-quality human proteins used in the company’s medications are derived from human plasma and human cell lines. The business focuses on immunotherapy, hematology, and critical care as its three therapeutic areas.

 

Key deliverables of the report: 

·        Market CAGR during the forecasting years 2022-2028

·        Detailed data highlighting key insights, industry components, and market strategies


·   Comprehensive information and estimation of the immunoglobulin market revenue growth in Europe and its influence on the parent market 


·        In-depth study of forthcoming trends in consumer behavioral patterns 


·        A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces Model


·   A wide-ranging study of factors that will challenge the Europe immunoglobulin market’s growth during the upcoming years

Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1. EUROPE IMMUNOGLOBULIN MARKET – SUMMARY

2. INDUSTRY OUTLOOK

2.1. IMPACT OF COVID-19 ON THE IMMUNOGLOBULIN MARKET

2.2. KEY INSIGHTS

2.2.1. DEVELOPMENT OF NEW PURIFICATION METHODS

2.2.2. INCREASING PREFERENCE FOR PERSONALIZED MEDICINES

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1. THREAT OF NEW ENTRANTS

2.3.2. THREAT OF SUBSTITUTES

2.3.3. BARGAINING POWER OF BUYERS

2.3.4. BARGAINING POWER OF SUPPLIERS

2.3.5. THREAT OF COMPETITIVE RIVALRY

2.4. MARKET ATTRACTIVENESS INDEX

2.5. VENDOR SCORECARD

2.6. KEY MARKET STRATEGIES

2.6.1. PRODUCT LAUNCHES & DEVELOPMENTS

2.6.2. PARTNERSHIPS & AGREEMENTS

2.7. MARKET DRIVERS

2.7.1. GROWTH IN THE GERIATRIC POPULATION

2.7.2. PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS

2.7.3. INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

2.8. MARKET CHALLENGES

2.8.1. HIGH COST OF THERAPY

2.8.2. HIGH RISK OF SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN

2.9. MARKET OPPORTUNITIES

2.9.1. INCREASING ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS

2.9.2. GROWING CLINICAL TRIALS

3. EUROPE IMMUNOGLOBULIN MARKET OUTLOOK - BY TYPE

3.1. IGG

3.2. IGA

3.3. IGM

3.4. IGE

3.5. IGD

4. EUROPE IMMUNOGLOBULIN MARKET OUTLOOK – BY DELIVERY MODE

4.1. INTRAVENOUS

4.2. SUBCUTANEOUS

4.3. INTRAMUSCULAR

5. EUROPE IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION

5.1. HYPOGAMMA GLOBULINEMIA

5.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

5.3. PRIMARY IMMUNODEFICIENCY DISEASES

5.4. MYASTHENIA GRAVIS

5.5. MULTIFOCAL MOTOR NEUROPATHY

5.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

5.7. INFLAMMATORY MYOPATHIES

5.8. SPECIFIC ANTIBODY DEFICIENCY

5.9. GUILLAIN-BARRE SYNDROME

5.10. OTHER APPLICATIONS

6. EUROPE IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER

6.1. HOSPITALS & CLINICS

6.2. HOMECARE

7. EUROPE IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL

7.1. HOSPITAL PHARMACY

7.2. SPECIALTY PHARMACY

7.3. OTHER SALES CHANNELS

8. EUROPE IMMUNOGLOBULIN MARKET – COUNTRY OUTLOOK

8.1. UNITED KINGDOM

8.2. GERMANY

8.3. FRANCE

8.4. SPAIN

8.5. ITALY

8.6. REST OF EUROPE

9. COMPETITIVE LANDSCAPE

9.1. BIOTEST AG

9.2. CHINA BIOLOGIC PRODUCTS INC

9.3. GRIFOLS SA

9.4. LFB GROUP

9.5. CSL BEHRING

9.6. KEDRION BIOPHARMA

9.7. OCTAPHARMA AG

9.8. TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.9. BIO PRODUCTS LABORATORY

9.10. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

9.11. PFIZER INC

9.12. SANQUIN PLASMA PRODUCTS BV

9.13. ADMA BIOLOGICS

9.14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

9.15. KAMADA LTD

10. RESEARCH METHODOLOGY & SCOPE

10.1. RESEARCH SCOPE & DELIVERABLES

10.2. SOURCES OF DATA

10.3. RESEARCH METHODOLOGY

List of Tables

TABLE 1: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 2: VENDOR SCORECARD

TABLE 3: EUROPE IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 4: EUROPE IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 5: EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 6: EUROPE IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 7: EUROPE IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 8: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

List of Figures

FIGURE 1: MARKET ATTRACTIVENESS INDEX

FIGURE 2: EUROPE IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)

FIGURE 3: EUROPE IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)

FIGURE 4: EUROPE IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)

FIGURE 5: EUROPE IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)

FIGURE 6: EUROPE IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)

FIGURE 7: EUROPE IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)

FIGURE 8: EUROPE IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)

FIGURE 9: EUROPE IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)

FIGURE 10: EUROPE IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)

FIGURE 11: EUROPE IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)

FIGURE 12: EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)

FIGURE 13: EUROPE IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)

FIGURE 14: EUROPE IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 15: EUROPE IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $ MILLION)

FIGURE 16: EUROPE IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)

FIGURE 17: EUROPE IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 18: EUROPE IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028 (IN $ MILLION)

FIGURE 19: EUROPE IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)

FIGURE 20: EUROPE IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $ MILLION)

FIGURE 21: EUROPE IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)

FIGURE 22: EUROPE IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)

FIGURE 23: EUROPE IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)

FIGURE 24: EUROPE IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)

FIGURE 25: EUROPE IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)

FIGURE 26: EUROPE IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)

FIGURE 27: EUROPE IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 28: EUROPE IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 29: EUROPE IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $ MILLION)

FIGURE 30: EUROPE IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)

FIGURE 31: UNITED KINGDOM IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 32: GERMANY IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 33: FRANCE IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 34: SPAIN IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 35: ITALY IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 36: REST OF EUROPE IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;